Widely read:
Anand Kumar/AI-Generated Image
Summary: Manipal Hospitals has built India's largest hospital network through acquisitions and has a strong operational track record. But with much of the IPO proceeds earmarked for debt repayment and the stock priced for near-perfect execution, investors should ask whether the valuation leaves enough room for error.
Manipal Hospitals did not become India's largest hospital chain by building. It became the largest by buying. Since FY21, it has absorbed five regional chains and 5,548 beds, enough to pass Apollo on licensed capacity. The interest bill behind the most recent of those deals swallowed all of last year's growth in operating profit. Clearing that debt is the main purpose of the Rs 9,275 crore issue, of which Rs 8,000 crore is fresh capital.
That makes the offer easier to judge than most. Our judgment is that it is richly priced.
Start with what you are paying
The price-to-earnings ratio, the price you pay for each rupee of annual profit, is 80 times. That number is unfair to the company, so set it aside. The Rs 5,310 crore of debt this issue repays was borrowed to buy Sahyadri, the hospital chain Manipal acquired last October. Take out the interest on it, at the roughly 9 per cent a year Manipal was paying, and tax the saving at 25 per cent. Counting Sahyadri for the full year rather than six months, profit is about Rs 749 crore. Add back the interest and it is about Rs 1,108 crore. At the upper band of Rs 590, that is 70 times earnings.
On enterprise value-to-EBITDA, which values the whole business, including its debt, against profit before interest, tax, depreciation and amortisation, Manipal trades at about 31 times, against Apollo at 33, Fortis at 34, and Max at 46. But read it carefully. That ratio leaves out interest and depreciation, and those are precisely Manipal's two problems. Interest consumed the whole of last year's operating profit growth, rising Rs 352 crore against a Rs 312 crore rise in operating profit. Depreciation rose by about a third as the acquired hospitals came onto the books, and it will keep rising.
Now look at the return you get for that. The Rs 8,000 crore of fresh capital roughly doubles net worth, from Rs 8,426 crore to Rs 16,426 crore, and on that enlarged base Manipal earns a return on equity of only about 7 per cent. For the buyer, it is still thinner: at Rs 590, for every Rs 100 you put in, the business earns about Rs 1.40 a year.
Three things Manipal does well
#1 Revenue per bed is rising
Average revenue per occupied bed (ARPOB), what a hospital collects from one bed in a day, has gone from Rs 61,742 in FY24 to Rs 68,938 in FY26. Manipal has moved steadily towards complex work: cardiac care, cancer, neurology, orthopaedics, digestive and kidney care. This work needs specialist doctors, advanced equipment and intensive care, so each patient bills more. The share of inpatient revenue from these specialities has climbed from 61.6 per cent to 64.3 per cent.
#2 Its beds turn over the fastest in the industry
Average length of stay has fallen from 2.9 days to 2.8, against 3.2 at Apollo, 4.1 at Max and 4.2 at Fortis. A hospital earns most of its money from a patient in the first day or two, through surgery, intensive care and tests. Discharge sooner and the same beds serve more admissions, with no fresh spending on buildings or equipment.
#3 It has fixed what it bought before
Manipal puts its own clinical protocols into a tired regional hospital, steers it towards complex work and buys supplies centrally. Columbia Asia, bought in FY22, lifted its operating margin from 30.5 per cent in FY24 to 33.8 per cent in FY26. AMRI in the east went from 21.3 per cent to 23.8 per cent over the same two years.
Four things that argue against the price
#1 The bed count flatters
Of the 13,037 licensed beds, 3,785 are not Manipal's at all. They belong to institutions such as the Manipal Academy of Higher Education, and Manipal runs them for a fee instead of billing the patient, producing management fees of Rs 52 crore, about half a per cent of revenue. That leaves 9,252 owned licensed beds, of which roughly 6,900 were open and treating patients on a full-year basis. Apollo operated 8,131 beds. Manipal is the largest chain by licence, not by beds in use.
#2 Occupancy is the lowest among the leaders
It runs at 64.5 per cent, against 67 per cent at Apollo, 68 per cent at Fortis and 76 per cent at Max. Sahyadri, bought last year for Rs 5,841 crore, is running at 62 per cent occupancy and Rs 40,555 per bed a day, about 40 per cent below the group. And it is not yet turning: its revenue per bed has fallen from Rs 41,727, and it lost Rs 41 crore after tax in the six months Manipal owned it.
#3 Goodwill is half the post-issue net worth
When a company pays more for a hospital than its assets are worth on paper, the difference sits on the balance sheet as goodwill. Manipal carries Rs 8,121 crore of it, close to half of net worth even after this issue. If an acquired hospital disappoints, the goodwill has to be written down and the charge lands straight on profit. Manipal has done it once, writing off Rs 114 crore on its HealthMap diagnostics arm in FY24.
#4 Most of the money goes backwards
Of the Rs 8,000 crore raised, Rs 5,553 crore redeems the Sahyadri debentures, including accrued interest and the prepayment penalty, and Rs 574 crore buys out Sahyadri's remaining minority shareholders. Under Rs 1,900 crore is left for anything else. The expansion the company talks about, new hospitals in Mumbai and Pune and about 2,400 more beds by 2030, will need money it has yet to raise or borrow. Return on capital employed is 11.3 per cent against a borrowing cost of about 9 per cent. That spread funds very little.
Manipal Hospital IPO details
| Total IPO size (Rs cr) | 9,275 |
| Offer for sale (Rs cr) | 1,275 |
| Fresh issue (Rs cr) | 8,000 |
| Price band (Rs) | 560-590 |
| Subscription dates | July 29 - July 31, 2026 |
| Purpose of issue | Debt repayment, minority stake acquisition in Sahyadri Hospitals and general corporate purposes |
Post-IPO
| M-cap (Rs cr) | 77,606 |
| Net worth (Rs cr) | 16,426 |
| Promoter holding (%) | 61.8 |
| Price/earnings ratio (P/E) | 80.3 |
| Price/book ratio (P/B) | 4.7 |
Financial history
| Key financials | 2Y CAGR (%) | FY26 | FY25 | FY24 |
|---|---|---|---|---|
| Revenue (Rs cr) | 29.4 | 10,336 | 8,242 | 6,172 |
| EBIT (Rs cr) | 22.6 | 1,932 | 1,620 | 1,286 |
| PAT (Rs cr) | 11.7 | 966 | 1,051 | 774 |
| Net worth (Rs cr) | 44.9 | 8,426 | 5,847 | 4,016 |
| Total debt (Rs cr) | 58.3 | 12,863 | 6,385 | 5,130 |
| EBIT stands for earnings before interest and tax PAT stands for profit after tax |
||||
Key ratios
| Key ratios | 3Y average (%) | FY26 | FY25 | FY24 |
|---|---|---|---|---|
| ROE (%) | 18 | 13.5 | 21.3 | 19.3 |
| ROCE (%) | 13.4 | 11.3 | 15 | 14 |
| EBIT margin (%) | - | 18.7 | 19.7 | 20.8 |
| Debt-to-equity (times) | - | 1.5 | 1.1 | 1.3 |
| ROE is return on equity, ROCE is return on capital employed |
||||
Operational history
| Operational metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| Bed capacity | 13,037 | 10,494 | 9,520 |
| Operational beds | 6,227 | 5,179 | 4,055 |
| Occupancy rate (%) | 64 | 67 | 65 |
| Average length of stay (in days) | 2.8 | 2.9 | 2.9 |
| Average revenue per occupied bed (Rs per day) | 68,938 | 63,312 | 61,742 |
| All years are restated | |||
Manipal versus listed peers
| Operational metric | Manipal | Apollo | Max | Fortis |
|---|---|---|---|---|
| Bed capacity | 13,037 | 10,970 | 6,131 | 6,100 |
| Occupancy rate (%) | 64 | 67 | 76 | 68 |
| ARPOB (Rs per day) | 68,938 | Not reported | 77,800 | 68,767 |
| ALOS (Average length of stay, in days) | 2.8 | 3.2 | 4.1 | 4.2 |
Our verdict
Manipal is a good business. It grows, it improves what it buys, and it moves patients through its beds faster than anyone else in the industry. None of that is in doubt.
The price is where the doubt lies. Manipal is asking 80 times last year's profit, and even after factoring in the interest savings from this issue and a full year's contribution from Sahyadri, it trades at about 70 times. That is roughly the same valuation as Apollo, Fortis, and Max, despite earning a 7 per cent return on its post-issue equity, having the lowest occupancy among the four, owning a large acquisition that is still loss-making and is likely two to three years away from turning around, and needing fresh capital for the expansion it has planned. You are not buying today's numbers. You are buying the assumption that Sahyadri will be fixed, occupancy will rise, and the goodwill on the balance sheet will hold.
That may well happen. Manipal has done it before. But the price already accounts for it, leaving the buyer with nothing if the integration runs late.
Investors who want the business rather than the listing pop can wait and watch four things: interest costs falling as the debt is repaid, group occupancy improving, Sahyadri's revenue per bed closing the gap with the rest of the network, and no further goodwill write-downs. Buy it when those are visible rather than promised.
Also read: How to think about IPOs
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
